Enhanced Anticoagulant Effect of Warfarin When Co-administered With Quercetin.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Journal of Pharmacy Technology Pub Date : 2022-12-01 Epub Date: 2022-09-24 DOI:10.1177/87551225221125667
Ruchit Patel, Allison Stine, Kimberly Zitko
{"title":"Enhanced Anticoagulant Effect of Warfarin When Co-administered With Quercetin.","authors":"Ruchit Patel, Allison Stine, Kimberly Zitko","doi":"10.1177/87551225221125667","DOIUrl":null,"url":null,"abstract":"A 79-year-old man on stable warfarin therapy for atrial fibrillation presented with an international normalized ratio (INR) of 7.5. The patient started quercetin supplementation several days prior to a routine INR monitoring appointment, taking 1 capsule daily. The supplement was made by Natural Factors and came in a dosage strength of 250 mg quercetin and 500 mg of Vitamin C. The patient previously had a stable INR between 2 and 3 for months, with an INR of 2.5 five days beforehand. The patient had no recent changes to contributing factors. The patient was taking stable amiodarone therapy for 4 months prior to this episode with no other critical INR values. No adverse bleeding events were reported by the patient. The patient had been taking 1 warfarin 7.5 mg tablet once daily with a weekly dose of 52.5 mg. After the INR of 7.5, the patient stopped taking the quercetin supplement indefinitely and restarted warfarin therapy after missing one day. Five days after the initial INR, the INR was found to be 2.5. The patient’s most recent labs were red blood cell (RBC) count of 4.48 103/ mm3, hemoglobin (HGB) of 13.7 g/dL, aspartate aminotransferase (AST) of 26 IU/L, alanine aminotransferase (ALT) of 18 IU/L, and a calculated creatinine clearance (CrCl) of 91 mL/min.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608098/pdf/10.1177_87551225221125667.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/87551225221125667","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

A 79-year-old man on stable warfarin therapy for atrial fibrillation presented with an international normalized ratio (INR) of 7.5. The patient started quercetin supplementation several days prior to a routine INR monitoring appointment, taking 1 capsule daily. The supplement was made by Natural Factors and came in a dosage strength of 250 mg quercetin and 500 mg of Vitamin C. The patient previously had a stable INR between 2 and 3 for months, with an INR of 2.5 five days beforehand. The patient had no recent changes to contributing factors. The patient was taking stable amiodarone therapy for 4 months prior to this episode with no other critical INR values. No adverse bleeding events were reported by the patient. The patient had been taking 1 warfarin 7.5 mg tablet once daily with a weekly dose of 52.5 mg. After the INR of 7.5, the patient stopped taking the quercetin supplement indefinitely and restarted warfarin therapy after missing one day. Five days after the initial INR, the INR was found to be 2.5. The patient’s most recent labs were red blood cell (RBC) count of 4.48 103/ mm3, hemoglobin (HGB) of 13.7 g/dL, aspartate aminotransferase (AST) of 26 IU/L, alanine aminotransferase (ALT) of 18 IU/L, and a calculated creatinine clearance (CrCl) of 91 mL/min.
华法林与槲皮素联合给药增强抗凝作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmacy Technology
Journal of Pharmacy Technology PHARMACOLOGY & PHARMACY-
CiteScore
1.50
自引率
0.00%
发文量
49
期刊介绍: For both pharmacists and technicians, jPT provides valuable information for those interested in the entire body of pharmacy practice. jPT covers new drugs, products, and equipment; therapeutic trends; organizational, legal, and educational activities; drug distribution and administration; and includes continuing education articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信